~~<i id='027DCF2619'><strike id='027DCF2619'><tt id='027DCF2619'><pre id='027DCF2619'></pre></tt></strike></i>~~

Home» focus» leisure time

leisure time

author：hotspot 2025-10-02 12:08:42 Page View：57

MADRID — Merck is paying billions of dollars to partner with Daiichi Sankyo on a series of cancer drugs, underscoring the excitement around targeted chemotherapy treatments.

The deal includes a $4 billion upfront payment and an additional $1.5 billion over the next two years. Up to $16.5 billion more is on the table depending on the success of the drugs in development.

The announcement on Thursday night in the United States came on the eve of one the cancer field’s biggest annual conferences, the European Society for Medical Oncology Congress, being held this year in Madrid.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The problem with charging patients to message their doctors
Next article： After affirmative action ruling, medical educators look to 'holistic review'

focus

Psychedelics group wrestles with new pharma identity

OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

Novo Nordisk obesity pill bests Wegovy in early trial

LISELOTTESABROE/AFP/GettyImagesApillbeingdevelopedbyDanishdrugmakerNovoNordiskmayleadtogreaterweight

After affirmative action ruling, medical educators look to 'holistic review'

AnnaMoneymaker/GettyImagesAfterhavingadaytoreadthroughtheSupremeCourt’sdecisiononaffirmativeaction,s

Hundreds of thousands march in Israel. Former security chiefs beg Netanyahu to halt legal overhaul

ThousandsofIsraelismarchtoJerusaleminprotestofplansbyPrimeMinisterBenjaminNetanyahu'sgovernmenttoove